VBL Therapeutics Reports Interim Topline Results From Phase 2 Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM)

Interim Data Demonstrate Statistically Significant Improvement in Overall Survival in Patients Treated With VB-111 in Combination With Bevacizumab (Avastin(R)) TEL AVIV, Israel, March 25, 2015 -- (Healthcare Sales & Marketing Network) -- VBL Therapeutic... Biopharmaceuticals, OncologyVBL Therapeutics, VB-111, glioblastoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news